Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting

Rhea-AI Summary

Karyopharm (Nasdaq: KPTI) said its late-breaking abstract from the Phase 3 SENTRY trial in myelofibrosis was accepted for an oral presentation at the ASCO 2026 Annual Meeting in Chicago.

The presentation covers 60 mg selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis (Abstract LBA6500), scheduled for June 2, 2026 at 9:45 a.m.–12:45 p.m. CT. According to the company, the presentation copy will be posted after the event under "Publications and Presentations" in Investor Relations.

News Market Reaction – KPTI

+2.57%

13 alerts

+2.57% Session close to close

+2.5% Peak in 1 hr 44 min

$215.96M Market Cap

0.4x Rel. Volume

In the Apr 21 session, KPTI gained 2.57%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.5% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement elevates the Phase 3 SENTRY program by securing a late‑breaking oral slot at ASCO ...

Analysis

This announcement elevates the Phase 3 SENTRY program by securing a late‑breaking oral slot at ASCO 2026, highlighting the clinical relevance of selinexor plus ruxolitinib in myelofibrosis. It follows topline SENTRY data released on Mar 24, 2026 and earlier milestones such as endpoint optimization and full enrollment of 353 patients. Investors may watch for full data details on June 2, 2026, future regulatory interactions, and any financing moves tied to the broader development plan.

Key Figures

Selinexor dose: 60 mg ASCO 2026 dates: May 29 to June 2, 2026 Presentation window: June 2, 2026, 9:45 a.m. to 12:45 p.m. CT

3 metrics

Selinexor dose 60 mg Dose of selinexor in Phase 3 SENTRY in combination with ruxolitinib

ASCO 2026 dates May 29 to June 2, 2026 American Society of Clinical Oncology (ASCO) Annual Meeting timing

Presentation window June 2, 2026, 9:45 a.m. to 12:45 p.m. CT Timing for the SENTRY late-breaking oral presentation at ASCO

Previous Clinical trial Reports

5 past events · Latest: Mar 24 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 24	Topline SENTRY results	Positive	-18.3%	Reported SENTRY met spleen-volume endpoint but missed symptom endpoint with OS signal.
Jan 12	Trial outlook update	Neutral	-5.6%	Outlined 2026 Phase 3 data expectations and preliminary 2025 revenue and liquidity.
Oct 08	Financing for SENTRY	Positive	+2.3%	Announced financings adding ≈$100M flexibility and extending runway beyond SENTRY readout.
Sep 10	SENTRY enrollment done	Positive	-1.9%	Completed enrollment of 353 patients in Phase 3 SENTRY in myelofibrosis.
Oct 31	Endpoint change SENTRY	Positive	+17.8%	Disclosed favorable SENTRY co-primary endpoint change after FDA feedback and Phase 1 data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial news for SENTRY has produced mixed to negative price reactions, including a -18.32% move on positive topline data.

Recent Company History

Over the past six months, Karyopharm has advanced the Phase 3 SENTRY program from endpoint optimization to full enrollment and topline data. A favorable co-primary endpoint change was announced on Oct 31, 2024, followed by SENTRY enrollment completion of 353 patients on Sep 10, 2025. Financing in Oct 2025 and early 2026 extended runway into the SENTRY readout. On Mar 24, 2026, topline results showed strong SVR35 but missed symptom endpoints. Today’s ASCO late‑breaking oral slot reinforces the trial’s clinical and scientific profile.

Key Terms

phase 3, randomized, double-blind, placebo-controlled, +3 more

7 terms

phase 3 medical

"The oral presentation will feature results from the Phase 3 SENTRY trial, a randomized..."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

randomized medical

"Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor..."

Randomized means participants or units in a study are assigned to different groups by chance rather than by choice, like flipping a coin to decide who gets a new treatment and who gets a comparison. For investors, randomized designs matter because they reduce bias and make results more trustworthy, so outcomes from randomized studies carry more weight when assessing regulatory approval, commercial prospects, and the risk that trial results will change a company’s valuation.

double-blind medical

"Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor..."

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor..."

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

myelofibrosis medical

"selinexor in combination with ruxolitinib in myelofibrosis.Presentation Details:Title: Selinexor..."

A bone marrow disorder in which healthy, spongy marrow is gradually replaced by scar tissue, like a garden soil turned to concrete so seeds can’t grow. That replacement reduces production of red and white blood cells and platelets, causing anemia, fatigue, infections and an enlarged spleen. Investors care because the condition creates demand for therapies, clinical trials and regulatory decisions that can materially affect drug sales and company valuations.

jak inhibitor medical

"Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial"

A JAK inhibitor is a type of medicine that blocks Janus kinase enzymes, which help cells send signals that drive inflammation and immune activity. By turning down that cellular “volume knob,” these drugs can reduce symptoms in autoimmune diseases and certain blood disorders. Investors watch JAK inhibitors because their effectiveness, safety profile, approval status, and patent position directly affect drug sales, market competition, and regulatory risk for companies developing or selling them.

hematologic malignancies medical

"Session Title: Oral Abstract Session - Hematologic Malignancies—Leukemia, Myelodysplastic..."

Hematologic malignancies are types of cancers that start in the blood or the organs responsible for blood production, like the bone marrow and lymph nodes. They matter because they can disrupt normal blood functions, leading to issues like weakness, infections, or abnormal growths, and often require specialized treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., April 21, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its late-breaking abstract was accepted for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 to June 2 in Chicago. The oral presentation will feature results from the Phase 3 SENTRY trial, a randomized, double-blind, placebo-controlled trial of 60 mg selinexor in combination with ruxolitinib in myelofibrosis.

Presentation Details:

• Title: Selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis: Phase 3 SENTRY trial
  
  
• Abstract Number: LBA6500 
  
  
• Session Title: Oral Abstract Session - Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
  
  
• Presentation Time: June 2, 2026, 9:45 a.m. to 12:45 p.m. Central Time
  
  
• Presenter: Dr. John Mascarenhas, Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders

Late-breaking abstracts for presentations being held on June 2, 2026 will be released by ASCO on Tuesday, June 2, 2026 at 8:00 a.m. Eastern Time / 7:00 a.m. Central Time. A copy of the SENTRY presentation being delivered at ASCO on June 2, 2026 will be available following the event under "Publications and Presentations" in the Investor section of the Company's website.

About the Phase 3 SENTRY Trial

SENTRY (XPORT-MF-034; NCT04562389) is a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 10⁹/L. Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume reduction ≥ 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline.

About Myelofibrosis

Myelofibrosis is a rare blood cancer that affects approximately 20,000 patients in the United States and 17,000 patients in the European Union¹. The disease causes bone marrow fibrosis (scarring in the bone marrow), which makes it difficult for the bone marrow to make healthy blood cells, splenomegaly (enlarged spleen), progressive anemia which often leads to symptoms like fatigue and weakness, and other disease associated symptoms including abdominal discomfort, pain under the left ribs, early satiety, night sweats and bone pain. The only approved class of therapies to treat myelofibrosis are JAK inhibitors, including ruxolitinib.

^1. Clarivate/DRG (2023)

About XPOVIO® (selinexor)

XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in multiple oncology indications, including: (i) in combination with VELCADE® (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma; and (iii) under accelerated approval in adult patients with diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. XPOVIO®/NEXPOVIO® is marketed in these respective ex-U.S. territories by Karyopharm's partners: Antengene, Menarini, Neopharm, and FORUS. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in myelofibrosis and endometrial cancer.

For more information about Karyopharm's products or clinical trials, please contact the Medical Information department at: Tel: +1 (888) 209-9326; Email: medicalinformation@karyopharm.com

XPOVIO^® (selinexor) is a prescription medicine approved:

• In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd).
  
  
• In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).
  
  
• For the treatment of adult patients with relapsed or refractory diffuse large B‐cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

SELECT IMPORTANT SAFETY INFORMATION

Warnings and Precautions

• Thrombocytopenia: Monitor platelet counts throughout treatment. Manage with dose interruption and/or reduction and supportive care.
  
  
• Neutropenia: Monitor neutrophil counts throughout treatment. Manage with dose interruption and/or reduction and granulocyte colony‐stimulating factors.
  
  
• Gastrointestinal Toxicity: Nausea, vomiting, diarrhea, anorexia, and weight loss may occur. Provide antiemetic prophylaxis. Manage with dose interruption and/or reduction, antiemetics, and supportive care.
  
  
• Hyponatremia: Monitor serum sodium levels throughout treatment. Correct for concurrent hyperglycemia and high serum paraprotein levels. Manage with dose interruption, reduction, or discontinuation, and supportive care.
  
  
• Serious Infection: Monitor for infection and treat promptly.
  
  
• Neurological Toxicity: Advise patients to refrain from driving and engaging in hazardous occupations or activities until neurological toxicity resolves. Optimize hydration status and concomitant medications to avoid dizziness or mental status changes.
  
  
• Embryo‐Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with a female partner of reproductive potential, of the potential risk to a fetus and use of effective contraception.
  
  
• Cataract: Cataracts may develop or progress. Treatment of cataracts usually requires surgical removal of the cataract.

Adverse Reactions

• The most common adverse reactions (≥20%) in patients with multiple myeloma who receive XVd are fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract and vomiting. Grade 3‐4 laboratory abnormalities (≥10%) are thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia and neutropenia. In the BOSTON trial, fatal adverse reactions occurred in 6% of patients within 30 days of last treatment. Serious adverse reactions occurred in 52% of patients. Treatment discontinuation rate due to adverse reactions was 19%.
  
  
• The most common adverse reactions (≥20%) in patients with multiple myeloma who receive Xd are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea and upper respiratory tract infection. In the STORM trial, fatal adverse reactions occurred in 9% of patients. Serious adverse reactions occurred in 58% of patients. Treatment discontinuation rate due to adverse reactions was 27%.
  
  
• The most common adverse reactions (incidence ≥20%) in patients with DLBCL, excluding laboratory abnormalities, are fatigue, nausea, diarrhea, appetite decrease, weight decrease, constipation, vomiting, and pyrexia. Grade 3‐4 laboratory abnormalities (≥15%) are thrombocytopenia, lymphopenia, neutropenia, anemia, and hyponatremia. In the SADAL trial, fatal adverse reactions occurred in 3.7% of patients within 30 days, and 5% of patients within 60 days of last treatment; the most frequent fatal adverse reactions was infection (4.5% of patients). Serious adverse reactions occurred in 46% of patients; the most frequent serious adverse reaction was infection (21% of patients). Discontinuation due to adverse reactions occurred in 17% of patients.

Use In Specific Populations

Lactation: Advise not to breastfeed.

For additional product information, including full prescribing information, please visit www.XPOVIO.com.

To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1‐888‐209‐9326 or FDA at 1‐800‐FDA‐1088 or www.fda.gov/medwatch.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the ability of selinexor to treat patients with multiple myeloma, endometrial cancer, myelofibrosis, diffuse large B-cell lymphoma and other diseases; expectations with respect to the clinical development plans, regulatory discussions and potential regulatory submissions for selinexor; and expectations regarding the timing, presentation and publication of additional data from the Phase 3 SENTRY trial. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO or that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; the ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; Karyopharm's results of clinical trials and preclinical trials, including subsequent analysis of existing data and new data received from ongoing and future trials; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical trials; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm's ability to enroll patients in its clinical trials; unplanned cash requirements and expenditures; substantial doubt exists regarding Karyopharm's ability to continue as a going concern; development or regulatory approval of drug candidates by Karyopharm's competitors for products or product candidates in which Karyopharm is currently commercializing or developing; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any of its products or product candidates. These and other risks are described under the caption "Risk Factors" in Karyopharm's Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission (SEC) on February 13, 2026, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharms-phase-3-sentry-trial-in-myelofibrosis-selected-for-late-breaking-oral-presentation-at-asco-2026-annual-meeting-302748864.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

What will KPTI present at ASCO 2026 on June 2, 2026?

Karyopharm will present Phase 3 SENTRY trial results of selinexor plus ruxolitinib in myelofibrosis. According to the company, the late-breaking oral session (Abstract LBA6500) covers 60 mg selinexor in JAK inhibitor–naïve patients and is scheduled June 2, 2026, 9:45 a.m.–12:45 p.m. CT.

When and where is the KPTI SENTRY oral presentation at ASCO 2026?

The SENTRY oral presentation is on June 2, 2026, 9:45 a.m.–12:45 p.m. Central Time in Chicago. According to the company, it is part of the Oral Abstract Session for Hematologic Malignancies and listed as Abstract LBA6500.

Who will present Karyopharm's SENTRY trial data at ASCO 2026?

Dr. John Mascarenhas will present the SENTRY trial data at ASCO 2026. According to the company, he is Professor of Medicine at Icahn School of Medicine at Mount Sinai and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders.

What treatment regimen does the Phase 3 SENTRY trial (KPTI) evaluate?

The SENTRY trial evaluates 60 mg selinexor combined with ruxolitinib in myelofibrosis patients who are JAK inhibitor–naïve. According to the company, it is a randomized, double-blind, placebo-controlled Phase 3 study.

When will ASCO release late-breaking abstracts for the June 2 sessions?

ASCO will release late-breaking abstracts on June 2, 2026 at 8:00 a.m. Eastern Time. According to the company, abstracts for presentations held June 2 will be released by ASCO at that time.

Where can investors find Karyopharm's SENTRY presentation after ASCO 2026?

A copy of the SENTRY presentation will be posted after ASCO under Investor Relations "Publications and Presentations." According to the company, the presentation will be available following the June 2, 2026 event.